Semaglutide is a game-changer! Melissa T
Thats $500 billion, that could be used for other things
From a public health perspective, the short-term cost of boosting GLP-1 drug coverage could lead to long-term cost savings associated with emergent and routine care for chronic conditions like cardiovascular disease, liver disease, heart failure, and depression, all of which are comorbid with obesity
GLP-1RA therapy was associated with reductions in total cholesterol, low-density lipoprotein cholesterol and triglyceride levels compared with placebo or other hypoglycaemic agents
For current market leaders, sustained dominance will hinge on an ability to navigate an increasingly uncertain regulatory and pricing environment and manage quality and safety concerns amid heightened scrutiny of GLP-1 drugs long-term effects and off-label use